The Center for International Blood and Marrow Transplant Research (CIBMTR) Launches Study of COVID-19 Vaccine Immunogenicity in Patients With Hematological Malignancies Who Have Received Cellular Therapy
The CIBMTR® (Center for International Blood and Marrow Transplant Research®) announces the launch of a large observational study, done in collaboration with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to understand the safety, efficacy, and durability of responses to COVID-19 vaccines in patients with hematological malignancies and non-malignant blood diseases who have received hematopoietic cell transplantation (HCT) or cellular therapies. The study is supported by National Marrow Donor Program (NMDP)/Be The Match®, The Leukemia & Lymphoma Society (LLS), the National Heart, Lung, and Blood Institute, the National Cancer Institute, the Fred Hutchinson Cancer Research Center, the Multiple Myeloma Research Foundation (MMRF), American Society for Transplantation and Cellular Therapy (ASTCT), and LabCorp.